The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Mutant p53 in cell-cell interactions
Abstract
p53 is an important tumor suppressor, and the complexities of p53 function in regulating cancer cell behaviour are well established. Many cancers lose or express mutant forms of p53, with evidence that the type of alteration affecting p53 may differentially impact cancer development and progression. It is also clear that in addition to cell-autonomous functions, p53 status also affects the way cancer cells interact with each other. In this review, we briefly examine the impact of different p53 mutations and focus on how heterogeneity of p53 status can affect relationships between cells within a tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant p53 can interact with transcription factors and cofactors to regulate multiple gene expression programs that promote cell proliferation, survival, invasion, and drug resistance.493”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [493]
In the citing paper
“Mutant p53 may not only lose the tumor suppressor function of wild-type p53 but also acquire new tumor-promoting functions, such as promoting tumor invasion, metastasis, and drug resistance.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [493]
In the citing paper
“mutant p53 GOF activities, including the facilitation of cell proliferation, invasion, survival, cancer-promoting metabolism, protumorigenic inflammation, and drug resistance, have been observed in a series of experimental models, and multiple GOF mechanisms have been proposed.140,493,494”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [493]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804 · cited 1×
“This feature is reminiscent of the oncogene cooperation in the transformation of primary cells, described some 40 yr ago (Land et al. 1983).”
BackgroundTracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · cited 2×
“Subclonal p53 mutations have been observed at varying frequencies in different cancer types, including lung (Jamal-Hanjani et al. 2017), skin (Albibas et al. 2018), and chronic lymphocytic leukemia (Nadeu et al. 2016), although a study of nine major cancer types showed that ∼95% of tumors are…”
BackgroundHigh burden and pervasive positive selection of somatic mutations in normal human skin
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., Wedge, D. C., Fullam, A., Alexandrov, L. B., Tubio, J. M., et al. (2015) · Science · doi:10.1126/science.aaa6806 · Cited by 1,770 · cited 1×
“Recent large scale sequencing studies have shown that apparently normal tissue harbors large numbers of cells carrying known oncogenic alterations, the frequency of which increases with age (Martincorena et al. 2015, 2018).”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 2×
“A variety of different compounds have been tested for their ability to restore the WT conformation and consequently the function of mutant p53 proteins (Muller and Vousden 2014).”
BackgroundSelf-citationSomatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396 · cited 1×
“In tumors, this genetic heterogeneity is further amplified by increased levels of DNA damage and enhanced still further by factors such as epigenetic, metabolic, and positional diversity (Martincorena and Campbell 2015).”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Self-citationGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 10×
“in response to various forms of DNA damage (Lang et al. 2004;Wijnhoven et al. 2007; Lee and Sabapathy 2008).”
BackgroundInfluentialTargeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · cited 1×
“However, APR-246 and its related compounds also show a variety of p53-independent activities that could underlie therapeutic efficacy (Bykov et al. 2018; Eriksson et al. 2019).”
BackgroundMetabolic Interactions in the Tumor Microenvironment
Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853 · cited 1×
“This composition has led to the description of tumors as “pseudoorgans” (Lyssiotis and Kimmelman 2017).”
BackgroundNon-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 2×
“…tissue by suppressing the expression of SDF-1/CXCL12, a chemokine that increases cell invasiveness (Moskovits et al. 2006) and the release of factors from p53-expressing hepatic stellate cells that promote macrophage polarization toward the tumor-suppressive M1 type (Lujambio et al. 2013).”
BackgroundRevisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
A Nonapoptotic Cell Death Process, Entosis, that Occurs by Cell-in-Cell Invasion
Overholtzer, M., Mailleux, A. A., Mouneimne, G., Normand, G., Schnitt, S. J., King, R. W., Cibas, E. S., & Brugge, J. S. (2007) · Cell · doi:10.1016/j.cell.2007.10.040 · Cited by 748
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1408 · Cited by 685
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569 · cited 6×
“Finally, p53 has also been shown to restrain the adrenergic transdifferentiation of neurons in murine oral tumors by promoting the release of vesicles containing the microRNA miR-34a.”
BackgroundInfluentialMutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Loss of p53 drives neuron reprogramming in head and neck cancer
Amit, M., Takahashi, H., Dragomir, M. P., Lindemann, A., Gleber-Netto, F. O., Pickering, C. R., Anfossi, S., Osman, A. A., Cai, Y., Wang, R., et al. (2020) · Nature · doi:10.1038/s41586-020-1996-3 · Cited by 483 · cited 1×
“These changes in innervation resulting from p53 loss contributed to cancer progression in mice and were correlated with a significant worse prognosis in human cancers (Amit et al. 2020).”
BackgroundA dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441 · cited 1×
“However, in vivo hematopoietic stem and progenitor cells (HSPCs) null for p53 outcompeted HSPCs expressing one mutant p53 and one WT allele in response to sublethal radiation, indicating the limitations of the DN effect (Boettcher et al. 2019).”
BackgroundThe gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Kadosh, E., Snir-Alkalay, I., Venkatachalam, A., May, S., Lasry, A., Elyada, E., Zinger, A., Shaham, M., Vaalani, G., Mernberger, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2541-0 · Cited by 378 · cited 2×
“The molecular mechanisms of mutant p53 action are still being debated, with the evidence for increased cancer-promoting capacity balanced by recent evidence that, in some tissues, mutant p53may even function to suppress tumorigenesis (Kadosh et al. 2020).”
Backgroundp53-Mediated Hematopoietic Stem and Progenitor Cell Competition
Bondar, T., & Medzhitov, R. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.002 · Cited by 342 · cited 1×
“For example, in the mouse hematopoietic stem cell niche, mildly damaged cells are outcompeted by healthy cells and enter senescence, a response that is dependent on p53 in the damaged, loser cells (Bondar and Medzhitov 2010; Marusyk et al. 2010).”
Backgroundp53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Self-citationCoppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 2×
“The consequences of SASP induction can be both tumorpromoting and tumor-limiting (Coppé et al. 2010), and the promalignant activities of SASP have been shown to be reduced by p53 (Coppé et al. 2008).”
BackgroundFeng, Z., Hu, W., Teresky, A. K., Hernando, E., Cordon-Cardo, C., & Levine, A. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708043104 · Cited by 264
A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3
Tajan, M., Hock, A. K., Blagih, J., Robertson, N. A., Labuschagne, C. F., Kruiswijk, F., Humpton, T. J., Adams, P. D., & Vousden, K. H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.005 · Cited by 230
Self-citationHui, L., Zheng, Y., Yan, Y., Bargonetti, J., & Foster, D. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209735 · Cited by 218 · cited 1×
“A positive role for mutant p53 in maintaining malignancies has also been shown in cell culture systems in vitro (Bossi et al. 2006; Hui et al. 2006) and in vivo, where inactivation of mutant p53 caused tumor shrinkage and improved survival in lymphomas (Alexandrova et al. 2015) and tumor shrinkage…”
BackgroundGuo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168 · cited 1×
“Several studies have shown that loss of WT p53 in normal stromal cells enhances tumorigenesis (Kiaris et al. 2005; Guo et al. 2013, 2017), demonstrating a tumor-suppressive role for p53beyond the cancer cells themselves.”
BackgroundIrradiation selects for p53-deficient hematopoietic progenitors.
Marusyk, A., Porter, C. C., Zaberezhnyy, V., & DeGregori, J. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000324 · Cited by 151 · cited 1×
“For example, in the mouse hematopoietic stem cell niche, mildly damaged cells are outcompeted by healthy cells and enter senescence, a response that is dependent on p53 in the damaged, loser cells (Bondar and Medzhitov 2010; Marusyk et al. 2010).”
Backgroundp53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123 · cited 1×
“However, APR-246 and its related compounds also show a variety of p53-independent activities that could underlie therapeutic efficacy (Bykov et al. 2018; Eriksson et al. 2019).”
BackgroundLoizou, E., Banito, A., Livshits, G., Ho, Y.-J., Koche, R. P., Sánchez-Rivera, F. J., Mayle, A., Chen, C.-C., Kinalis, S., Bagger, F. O., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1391 · Cited by 88
Expanding the p53 regulatory network: LncRNAs take up the challenge
Grossi, E., Sánchez, Y., & Huarte, M. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.07.011 · Cited by 78 · cited 6×
“Finally, p53 has also been shown to restrain the adrenergic transdifferentiation of neurons in murine oral tumors by promoting the release of vesicles containing the microRNA miR-34a.”
BackgroundInfluentialBuganim, Y., Solomon, H., Rais, Y., Kistner, D., Nachmany, I., Brait, M., Madar, S., Goldstein, I., Kalo, E., Adam, N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2661 · Cited by 77
p53 pathway is involved in cell competition during mouse embryogenesis
Zhang, G., Xie, Y., Zhou, Y., Xiang, C., Chen, L., Zhang, C., Hou, X., Chen, J., Zong, H., & Liu, G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617414114 · Cited by 69 · cited 2×
“Interestingly, the fate of the p53-driven loser cells could be apoptosis (Bowling et al. 2018) or reduced proliferation (Zhang et al. 2017), suggesting that the response to p53 may differ depending on context.”
BackgroundColonization of adjacent stem cell compartments by mutant keratinocytes
BRASH, D., ZHANG, W., GROSSMAN, D., & TAKEUCHI, S. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.08.006 · Cited by 32 · cited 1×
“Interestingly, other studies have suggested that the expansion of mutant p53-expressing clones of keratinocytes is restrained in normal epithelium but released in response to UV exposure, which allows the mutant p53-expressing clones to expand (Brash et al. 2005).”
Background
Research works printed but not linked: 122
- 10.1101/cshperspect.a026260 · DOI
- 10.1158/0008-5472.CAN-10-1146 · DOI
- 10.3390/ijms21103452 · DOI
- 10.1016/j.jid.2017.07.844 · DOI
- 10.1038/nature14430 · DOI · Paper page
- 2017, P53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo, Cell Death Dis, 8, e2661-5
- 10.1038/s41420-020-0251-x · DOI
- 10.1073/pnas.1808314115 · DOI
- 10.1073/pnas.1719076115 · DOI
- 10.1038/s41576-020-0262-8 · DOI · Paper page
- 10.1038/onc.2008.445 · DOI
- 10.1002/1878-0261.12736 · DOI
- 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
- 10.1016/j.celrep.2019.12.028 · DOI · Paper page
- 10.1038/sj.onc.1209026 · DOI · Paper page
- 10.1002/path.4356 · DOI
- 10.1038/s41467-018-04167-y · DOI
- 10.1242/dev.167486 · DOI
- 10.1038/nature23304 · DOI
- 10.1038/sj.onc.1203434 · DOI · Paper page
- 10.1038/s41467-020-17596-5 · DOI
- 10.1186/s12916-017-0900-y · DOI · Paper page
- 10.1038/s41467-019-13542-2 · DOI
- 10.1038/s41467-018-03224-w · DOI · Paper page
- 10.1146/annurev-pathol-121808-102144 · DOI · Paper page
- 10.1016/j.canlet.2016.03.046 · DOI
- 10.1126/science.1241628 · DOI
- 10.1016/j.cmet.2014.01.012 · DOI
- 10.1089/omi.2010.0084 · DOI
- 10.3390/biom10040548 · DOI · Paper page
- 10.1038/s41598-017-13002-1 · DOI
- 10.1016/j.molcel.2014.10.013 · DOI · Paper page
- 10.1038/356215a0 · DOI · Paper page
- 10.1016/j.celrep.2019.07.001 · DOI · Paper page
- 10.1007/s00018-020-03677-7 · DOI
- 10.1016/j.ccell.2020.05.010 · DOI · Paper page
- 10.1038/s41568-018-0073-9 · DOI · Paper page
- 10.1016/j.stem.2019.06.011 · DOI
- 10.1038/onc.2016.502 · DOI · Paper page
- 10.1038/nrg.2016.145 · DOI · Paper page
- 10.1101/gad.190678.112 · DOI · Paper page
- 10.1101/gad.340976.120 · DOI
- 10.1038/s41586-020-2315-8 · DOI
- 10.1158/0008-5472.CAN-12-3810 · DOI
- 10.1038/cdd.2013.17 · DOI · Paper page
- 10.3390/ijms21134675 · DOI · Paper page
- 10.1038/ncb1853 · DOI · Paper page
- 10.1038/srep08907 · DOI
- 10.1186/s40170-018-0191-6 · DOI · Paper page
- 10.1038/s41556-017-0009-8 · DOI
- 10.1016/j.ccr.2012.04.027 · DOI · Paper page
- 10.1038/nature21703 · DOI · Paper page
- 10.1172/JCI81135 · DOI · Paper page
- 10.1038/nrc1877 · DOI · Paper page
- 10.1038/nature12634 · DOI · Paper page
- 10.1073/pnas.1431692100 · DOI · Paper page
- 10.1016/0092-8674(93)90461-X · DOI · Paper page
- 10.1016/j.cell.2010.03.015 · DOI · Paper page
- 10.1158/0008-5472.CAN-04-3791 · DOI · Paper page
- 10.1038/cdd.2017.185 · DOI · Paper page
- 10.1002/1097-0215(20010720)95:4<232::AID-IJC1040>3.0.CO;2-5 · DOI
- 10.1038/ncb3509 · DOI · Paper page
- 10.1016/j.molcel.2018.06.012 · DOI · Paper page
- 10.1242/jcs.022822 · DOI
- 10.1038/sj.onc.1203135 · DOI
- 10.1093/jmcb/mjz063 · DOI
- 10.1128/MCB.16.9.4952 · DOI · Paper page
- 10.1038/s41467-018-05368-1 · DOI
- 10.1371/journal.pone.0061353 · DOI
- 10.1016/j.molcel.2015.12.014 · DOI · Paper page
- 10.1177/1947601911413466 · DOI · Paper page
- 10.1242/jcs.163675 · DOI
- 10.1038/s41418-018-0246-9 · DOI · Paper page
- 10.1126/science.aau3879 · DOI · Paper page
- 10.1073/pnas.1009376107 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-2323 · DOI
- 10.1016/j.cell.2009.11.026 · DOI · Paper page
- 10.1182/blood-2015-07-659144 · DOI · Paper page
- 10.1038/s41467-020-16245-1 · DOI
- 10.1021/acs.biochem.9b00796 · DOI
- 10.18632/oncotarget.382 · DOI
- 10.1038/s41467-018-07339-y · DOI
- 10.1016/j.semcancer.2019.05.009 · DOI
- 10.1016/j.bbapap.2013.03.014 · DOI
- 10.3390/biom10020307 · DOI
- 10.3390/ijms21249648 · DOI
- 10.1002/cncr.33143 · DOI · Paper page
- 10.1038/s41467-017-01117-y · DOI
- 10.1177/1947601911408889 · DOI · Paper page
- 10.1016/j.celrep.2019.02.025 · DOI
- 10.1016/j.devcel.2013.06.012 · DOI · Paper page
- 10.1084/jem.20100797 · DOI
- 10.1016/j.ccell.2018.07.004 · DOI · Paper page
- 10.1038/s41698-018-0074-x · DOI
- 10.1242/jcs.099663 · DOI
- 10.1093/jmcb/mjz071 · DOI
- 10.3390/ijms20246197 · DOI · Paper page
- 10.1093/carcin/bgaa117 · DOI
- 2016, Oncogenic intra-p53 family member interactions in human cancers, Front Oncol, 6, 77
- 10.1038/cdd.2017.174 · DOI · Paper page
- 10.1136/esmoopen-2018-EACR25.46 · DOI
- 10.1016/j.semcancer.2019.05.011 · DOI
- 10.1038/onc.2016.360 · DOI
- 10.1016/j.molcel.2013.05.002 · DOI
- 10.1002/humu.10185 · DOI · Paper page
- 10.1038/sj.onc.1201041 · DOI
- 10.1093/emboj/17.16.4657 · DOI · Paper page
- 10.1038/s41467-019-10968-6 · DOI · Paper page
- 10.1126/science.1243148 · DOI · Paper page
- 10.1038/ncomms11373 · DOI · Paper page
- 10.1073/pnas.0908151106 · DOI · Paper page
- 10.1016/j.celrep.2018.05.081 · DOI
- 10.1016/j.bbcan.2017.12.004 · DOI
- 10.1016/j.molcel.2019.11.009 · DOI
- 10.1038/s41586-019-1450-6 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-4681 · DOI
- 10.1002/path.5328 · DOI
- 10.1093/carcin/bgr270 · DOI
- 10.1111/cas.14084 · DOI
- 10.1093/jmcb/mjaa040 · DOI · Paper page
- 10.1016/j.celrep.2020.107879 · DOI
- 10.3389/fonc.2020.595187 · DOI · Paper page
Cited by
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Pilley, S., Rodriguez, T. A., & Vousden, K. H.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2021-04-01
- Volume
- 35
- Issue
- 7-8
- Pages
- 433-448
- ISSN
- 0890-9369
- 1549-5477
- Cited by
- 53
- References
- 36
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.